Cancer Stem Cell News Volume 11.45 | Dec 14 2022

    0
    26








    2022-12-14 | CSCN 11.45


    Cancer Stem Cell News by STEMCELL Technologies
    Vol. 11.45 – 14 December, 2022
    TOP STORY

    NARF Is a Hypoxia-Induced Coactivator for OCT4-Mediated Breast Cancer Stem Cell Specification

    Researchers identified nuclear prelamin A recognition factor (NARF) as a hypoxia-inducible, hypoxia-inducible factor 1 target gene in human breast cancer cells.
    [Science Advances]

    Full Article
    Explore tools and resources for your return to the lab
    PUBLICATIONSRanked by the impact factor of the journal

    Characterization of an RNA Binding Protein Interactome Reveals a Context-Specific Post-Transcriptional Landscape of MYC-Amplified Medulloblastoma

    The authors identified binding targets of Musashi-1 in normal neural and group 3 medulloblastoma stem cells and then cross referenced these data with unbiased large-scale screens at the transcriptomic, translatomic, and proteomic levels.
    [Nature Communications]

    Full Article

    A Pro B Cell Population Forms the Apex of the Leukemic Hierarchy in Hoxa9/Meis1-Dependent AML

    Investigators showed that Hoxa9/Meis1-dependent AML was hierarchically organized and tracked the developmental potential of leukemic stem cell phenotypes.
    [Leukemia]

    Full Article

    FBXL2 Promotes E47 Protein Instability to Inhibit Breast Cancer Stemness and Paclitaxel Resistance

    Scientists demonstrated that the F-box protein FBXL2 was a critical negative regulator of breast cancer stem cell stemness and that downregulation of FBXL2 played a causal role in TNBC drug resistance.
    [Oncogene]

    Abstract

    EZH2 Interacts with HP1BP3 to Epigenetically Activate WNT7B That Promotes Temozolomide Resistance in Glioblastoma

    Researchers clarified a new oncogenic mechanism of enhancer of Zeste Homolog 2 (EZH2) by which it interacted with heterochromatin protein 1 binding protein 3 (HP1BP3) and epigenetically activated WNT7B thereby promoting TMZ resistance in glioma stem cells.
    [Oncogene]

    Abstract

    Glioblastoma Stem Cells Express Non-Canonical Proteins and Exclusive Mesenchymal-Like or Non-Mesenchymal-Like Protein Signatures

    To characterize protein expression in glioblastoma CSCs (GSCs), scientists performed in-depth proteogenomic analysis of patient-derived GSCs by RNA-sequencing and mass-spectrometry.
    [Molecular Oncology]

    Abstract

    GAS5 Attenuates the Malignant Progression of Glioma Stem-Like Cells by Promoting E-cadherin

    The authors established two highly malignant glioma stem-like cell (GSC) lines from clinical surgical specimens and found that the long non-coding RNA growth arrest-specific 5 (GAS5) expression was downregulated in GSCs and high-grade glioma tissues.
    [Cancer Gene Therapy]

    Abstract

    Aporphine and Isoquinoline Derivatives Block Glioblastoma Cell Stemness and Enhance Temozolomide Cytotoxicity

    Based on the cytotoxic properties of aporphine compounds, researchers evaluated the biological effect of 12 compounds obtained through total synthesis of (±)-apomorphine hydrochloride against glioblastoma cells.
    [Scientific Reports]

    Full Article

    Triiodothyronine Lowers the Potential of Colorectal Cancer Stem Cells In Vitro

    Scientists reported that triiodothyronine exerted significant impact on CSCs of two colorectal cancer cell lines cultured in the form of colonospheres.
    [Oncology Reports]

    Abstract

    TWIST1 Activates Cancer Stem Cell Marker Genes to Promote Epithelial-Mesenchymal Transition and Tumorigenesis in Esophageal Squamous Cell Carcinoma

    Investigators identified a role for Twist-related protein 1 (TWIST1) in the establishment of esophageal squamous cell carcinoma CSC-like phenotype, facilitating the transformation of non-CSCs to CSCs.
    [BMC Cancer]

    Full Article
    Easy250 EasySep Magnet for rapid immune cell isolation from large-volume samples.
    REVIEWS

    Biology, Vulnerabilities, and Clinical Applications of Circulating Tumor Cells

    Scientists review the progress made in understanding biological features of circulating tumor cells and provide insight into exploiting these developments to design future clinical tools
    [Nature Reviews Cancer]

    Full Article

    Cancer Stem Cells (CSCs): Key Player of Radiotherapy Resistance and Its Clinical Significance

    The authors discuss CSCs, radioresistance-mediated CSCs development, epithelial-to-mesenchymal transition associated with CSCs, the role of exosomes in radioresistance development, and the current state of radiation therapy.
    [Biomarkers]

    Abstract
    INDUSTRY AND POLICY NEWS

    Calidi Biotherapeutics Receives Funding from the California Institute for Regenerative Medicine (CIRM) to Advance SuperNova-1 and NeuroNova-2 Development Programs

    Calidi Biotherapeutics, Inc. announced that the CIRM has awarded the company a $3.1 million grant to support the continued development of the company’s Supernova-1 pre-clinical program through an Investigational New Drug application.
    [Calidi Biotherapeutics, Inc.]

    Press Release
    FEATURED EVENT

    AACR Special Conference: Pediatric Hematologic Malignancies

    February 19 – 22, 2023
    New Orleans, Louisiana, United States

    > See All Events

    JOB OPPORTUNITIES

    Faculty Positions – Translational Biomedical Research

    Rutgers Biomedical and Health Sciences – Newark, New Jersey, United States

    Faculty Positions – Life Sciences

    Westlake University – Hangzhou, China

    Postdoctoral Researcher – Cancer Biology

    Flanders Institute for Biotechnology – Leuven, Belgium

    Postdoctoral Scholar – Glioblastoma Tumor Growth

    University of California Irvine – Irvine, California, United States

    Sales Specialist – Oncology Melanoma

    Novartis – Boston, Massachusetts, United States

    > See All Jobs

    Submit an article, publication, job or event
    Brought to you by
    stemcell-logo-for newsletter-2
    Cancer Stem Cell News Twitter